Podcast Beta
Questions and Answers
What is the generic name of Brilinta?
Brilinta is not effective in reducing stent thrombosis.
False
What was Brilinta studied against in the PLATO trial?
Clopidogrel
What conditions does Brilinta aim to reduce the rate of?
Signup and view all the answers
Brilinta is contraindicated in patients with a history of intracranial hemorrhage.
Signup and view all the answers
What are some common side effects of Brilinta?
Signup and view all the answers
The starting dose of Brilinta for managing ACS is a ____-mg loading dose.
Signup and view all the answers
When should the daily maintenance dose of Brilinta be adjusted to 60 mg?
Signup and view all the answers
What is the mechanism of action of Brilinta?
Signup and view all the answers
Brilinta can cause significant, sometimes fatal bleeding.
Signup and view all the answers
What should be avoided during Brilinta treatment?
Signup and view all the answers
Match the following symptoms with their relation to Brilinta treatment:
Signup and view all the answers
What percentage of patients treated with Brilinta developed dyspnea in clinical trials?
Signup and view all the answers
Study Notes
Brilinta Overview
- Brilinta (Ticagrelor) is classified as a platelet aggregation inhibitor.
- It is effective in reducing stent thrombosis, improving patient outcomes post-ACS.
Clinical Trials
- The PLATO trial compared BRILINTA 90 mg to clopidogrel, both in conjunction with aspirin and standard therapies.
- This study included patients with acute coronary syndrome (ACS), comprising STEMI, NSTEMI, and unstable angina patients.
Indications
- BRILINTA is indicated for reducing cardiovascular death, myocardial infarction (MI), and stroke in ACS patients or those with a history of MI.
- It demonstrates superiority over clopidogrel for at least the first 12 months after ACS.
Safety Considerations
- Like other antiplatelet agents, BRILINTA carries a risk of significant and potentially fatal bleeding.
Side Effects
- Common side effects include:
- Chest pain
- Shortness of breath
- Irregular heartbeat
- Persistent nosebleeds
- Easy bruising and skin spots
Contraindications
- Avoid use in patients with a history of intracranial hemorrhage or active pathological bleeding.
- Contraindicated in patients with hypersensitivity to ticagrelor or its components.
Drug Interactions
- Caution is required with strong CYP3A inhibitors and inducers, as these can significantly alter ticagrelor metabolism and elevation in adverse event risks.
Dosing Guidelines
- Initiate treatment with a 180-mg loading dose for ACS management.
- Follow with a 90 mg twice daily for the first year post-ACS, then reduce to 60 mg twice daily.
Administration Protocol
- Alongside BRILINTA, a daily maintenance dose of aspirin (75-100 mg) is recommended.
Mechanism of Action
- Ticagrelor and its active metabolite inhibit the P2Y12 ADP receptor on platelets, preventing activation and aggregation.
Savings Opportunities
- The BRILINTA Savings Card allows commercially insured patients to pay as low as $18 for a 3-month supply with each refill.
ACS Guidelines
- In patients undergoing medical therapy for ACS without revascularization, dual antiplatelet therapy (DAPT) should last at least 12 months.
Dyspnea Incidence
- Approximately 14% of patients treated with BRILINTA reported dyspnea, typically mild to moderate, with rare instances leading to discontinuation of the drug.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Explore essential concepts related to Brilinta, the drug containing Ticagrelor. Learn about its classification, efficacy in stent thrombosis reduction, and insights from key clinical trials like PLATO. This quiz is perfect for medical students or healthcare professionals wanting to reinforce their knowledge of this platelet aggregation inhibitor.
